All In Biotech

Drug Trial Radar · NCT02194699

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Last checked: Nov 20, 2026Latest source record: May 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 856 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

856

Actual

Start

Oct 30, 2014

Primary completion

May 10, 2017

Study completion Sep 21, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Conditions

  • Uncontrolled Asthma

Interventions

  • Experimental: TralokinumabBiological

    Tralokinumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised Asthma Exacerbation Rate (AAER) up to Week 52Time frame: Baseline (Week 0) up to Week 52

Locations

234 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Hoover, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Buena Park, California

  • Research Site

    Encinitas, California

  • Research Site

    Lakewood, California

  • Research Site

    Lomita, California

  • Research Site

    Northridge, California

  • Research Site

    Palmdale, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Francisco, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Ventura, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Centennial, Colorado

  • Research Site

    Celebration, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    New Port Richey, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Palmetto Bay, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Columbus, Georgia

  • Research Site

    Gainesville, Georgia

  • Research Site

    Savannah, Georgia

Showing 40 of 234 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.